# Chipscreen NewWay Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chipscreen-newway-biosciences

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Total disclosed funding: $39M
- Latest round: Series A (Jul 21, 2025)
- Investors on record: 3

## About

Founded in 2021 and based in Chengdu, China, Chipscreen NewWay Biosciences is a biotechnology company primarily engaged in developing large molecules and other novel therapeutic technologies. The company is an affiliated company of ChipScreen, a biotech company based in Shenzhen, China.

In July 2025, Chipscreen NewWay Biosciences raised CNY 50.00 million in series A++ funding from new investor BIO-TOWN Capital.

Chipscreen NewWay Biosciences utilizes novel therapeutic approaches and technologies, including large molecules such as antibodies and nucleic acid drugs, to develop innovative drugs with novel mechanisms of action that meet clinical needs in multiple therapeutic areas, including oncology, providing patients with new treatment options and novel therapeutic approaches The company generates revenue from developing drugs from large molecules technologies.

## Funding rounds

- Series A, Jul 21, 2025, $7M — BIO-TOWN Capital
- Series A, Aug 2, 2022, $32M — Essence Capital, Shunlian Capital

## Investors

- Essence Capital — Series A
- Shunlian Capital — Series A
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series A